Royal London Asset Management Ltd. reduced its stake in shares of Zoetis Inc (NYSE:ZTS) by 1.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 192,481 shares of the company’s stock after selling 2,272 shares during the period. Royal London Asset Management Ltd.’s holdings in Zoetis were worth $21,813,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the stock. Huntington National Bank grew its holdings in Zoetis by 3.0% during the 2nd quarter. Huntington National Bank now owns 2,975 shares of the company’s stock worth $338,000 after acquiring an additional 87 shares during the period. Rehmann Capital Advisory Group grew its holdings in Zoetis by 4.0% during the 1st quarter. Rehmann Capital Advisory Group now owns 2,550 shares of the company’s stock worth $257,000 after acquiring an additional 97 shares during the period. Louisiana State Employees Retirement System grew its holdings in Zoetis by 0.4% during the 1st quarter. Louisiana State Employees Retirement System now owns 25,300 shares of the company’s stock worth $2,547,000 after acquiring an additional 100 shares during the period. Abbrea Capital LLC grew its holdings in Zoetis by 2.9% during the 1st quarter. Abbrea Capital LLC now owns 3,530 shares of the company’s stock worth $355,000 after acquiring an additional 100 shares during the period. Finally, Ipswich Investment Management Co. Inc. grew its holdings in Zoetis by 4.2% during the 2nd quarter. Ipswich Investment Management Co. Inc. now owns 2,484 shares of the company’s stock worth $282,000 after acquiring an additional 100 shares during the period. 90.08% of the stock is owned by institutional investors and hedge funds.
In other Zoetis news, insider Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $113.09, for a total transaction of $692,450.07. Following the transaction, the insider now owns 46,812 shares of the company’s stock, valued at approximately $5,293,969.08. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Glenn David sold 8,191 shares of Zoetis stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $102.22, for a total transaction of $837,284.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,537 shares of company stock worth $3,184,955. Insiders own 0.29% of the company’s stock.
ZTS stock traded up $0.87 during mid-day trading on Tuesday, reaching $124.83. 655,358 shares of the company traded hands, compared to its average volume of 1,975,770. The firm has a market cap of $59.87 billion, a PE ratio of 39.88, a price-to-earnings-growth ratio of 3.16 and a beta of 0.92. The company has a current ratio of 4.17, a quick ratio of 2.87 and a debt-to-equity ratio of 2.74. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $125.88. The company has a 50 day simple moving average of $115.71.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 EPS. On average, equities analysts predict that Zoetis Inc will post 3.57 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be given a dividend of $0.164 per share. The ex-dividend date is Thursday, July 18th. This represents a $0.66 annualized dividend and a dividend yield of 0.53%. Zoetis’s dividend payout ratio is currently 21.09%.
A number of analysts have weighed in on ZTS shares. Guggenheim started coverage on Zoetis in a report on Thursday, May 23rd. They set a “buy” rating and a $114.00 price target for the company. Stifel Nicolaus increased their price target on Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. Gabelli downgraded Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target for the company. in a report on Thursday, May 2nd. They noted that the move was a valuation call. SunTrust Banks raised their target price on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research note on Tuesday. Finally, Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Zoetis currently has an average rating of “Buy” and a consensus target price of $115.13.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Candlestick
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.